EZH2 in Hepatocellular Carcinoma: Progression, Immunity, and Potential Targeting Therapies

Overview

Journal Exp Hematol Oncol

Publisher Biomed Central

Specialty Hematology

Date 2023 Jun 2

PMID 37268997

Authors

Bohan Wang

Yachong Liu

Zhibin Liao

Haofeng Wu

Bixiang Zhang

Lei Zhang

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) is the leading cause of cancer-related death. The accumulation of genetic and epigenetic changes is closely related to the occurrence and development of HCC. Enhancer of zeste homolog 2 (EZH2, a histone methyltransferase) is suggested to be one of the principal factors that mediates oncogenesis by acting as a driver of epigenetic alternation. Recent studies show that EZH2 is widely involved in proliferation and metastasis of HCC cells. In this review, the functions of EZH2 in HCC progression, the role of EZH2 in tumor immunity and the application of EZH2-related inhibitors in HCC therapy are summarized.

Citing Articles

Comprehensive systems biology analysis of microRNA-101-3p regulatory network identifies crucial genes and pathways in hepatocellular carcinoma.

Rahimi-Farsi N, Ghorbani A, Mottaghi-Dastjerdi N, Shahbazi T, Bostanian F, Mohseni P J Genet Eng Biotechnol. 2025; 23(1):100471.

PMID: 40074445 PMC: 11883376. DOI: 10.1016/j.jgeb.2025.100471.

Enhancer zeste homolog 2 (EZH2) targeting by small interfering RNA (siRNA); recent advances and prospect.

Hsu C, Mohammed A, Hjazi A, Uthirapathy S, Renuka J, Singh A Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 39960560 DOI: 10.1007/s00210-025-03883-9.

BRD4 interacting genes as prognostic biomarkers in hepatocellular carcinoma for optimized treatment strategies.

Zhang H, Yu J, Zhang F, Liu Q, Pan J, Wen P Sci Rep. 2025; 15(1):5617.

PMID: 39955326 PMC: 11830049. DOI: 10.1038/s41598-025-89614-9.

Key oncogenes and candidate drugs for hepatitis-B-driven hepatocellular carcinoma progression.

Ruan L, Fang N, Zhao X, Chen W, Wu Z, Wu X Discov Oncol. 2025; 16(1):116.

PMID: 39903352 PMC: 11794919. DOI: 10.1007/s12672-025-01851-6.

Exploring oncogenic roles and clinical significance of EZH2: focus on non-canonical activities.

Wozniak M, Czyz M Ther Adv Med Oncol. 2025; 17():17588359241306026.

PMID: 39776536 PMC: 11705335. DOI: 10.1177/17588359241306026.

References

Chan L, Li C, Xia W, Hsu J, Lee H, Cha J . IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. J Clin Invest. 2019; 129(8):3324-3338. PMC: 6668668. DOI: 10.1172/JCI126022. View

Liu C, Xu J, Zhou Z, Jin L, Yu X, Xiao G . Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma. Br J Cancer. 2018; 119(1):80-88. PMC: 6035200. DOI: 10.1038/s41416-018-0144-4. View

Sandoval J, Esteller M . Cancer epigenomics: beyond genomics. Curr Opin Genet Dev. 2012; 22(1):50-5. DOI: 10.1016/j.gde.2012.02.008. View

Chan-Penebre E, Armstrong K, Drew A, Grassian A, Feldman I, Knutson S . Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: and Preclinical Models. Mol Cancer Ther. 2017; 16(5):850-860. DOI: 10.1158/1535-7163.MCT-16-0678. View

van Mierlo G, Veenstra G, Vermeulen M, Marks H . The Complexity of PRC2 Subcomplexes. Trends Cell Biol. 2019; 29(8):660-671. DOI: 10.1016/j.tcb.2019.05.004. View

Mirzaei S, Gholami M, Hushmandi K, Hashemi F, Zabolian A, Canadas I . The long and short non-coding RNAs modulating EZH2 signaling in cancer. J Hematol Oncol. 2022; 15(1):18. PMC: 8892735. DOI: 10.1186/s13045-022-01235-1. View

Antonysamy S, Condon B, Druzina Z, Bonanno J, Gheyi T, Zhang F . Structural context of disease-associated mutations and putative mechanism of autoinhibition revealed by X-ray crystallographic analysis of the EZH2-SET domain. PLoS One. 2013; 8(12):e84147. PMC: 3868555. DOI: 10.1371/journal.pone.0084147. View

Wang H, Cao C, Wei X, Shen K, Shu Y, Wan X . A comparison between drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis of six randomized controlled trials. J Cancer Res Ther. 2020; 16(2):243-249. DOI: 10.4103/jcrt.JCRT_504_19. View

You Z, Peng D, Cao Y, Zhu Y, Yin J, Zhang G . P53 suppresses the progression of hepatocellular carcinoma via miR-15a by decreasing OGT expression and EZH2 stabilization. J Cell Mol Med. 2021; 25(19):9168-9182. PMC: 8500955. DOI: 10.1111/jcmm.16792. View

10.

Huang Z, Zhou J, Peng Y, He W, Huang C . The role of long noncoding RNAs in hepatocellular carcinoma. Mol Cancer. 2020; 19(1):77. PMC: 7161154. DOI: 10.1186/s12943-020-01188-4. View

11.

Liu H, Liu Y, Liu W, Zhang W, Xu J . EZH2-mediated loss of miR-622 determines CXCR4 activation in hepatocellular carcinoma. Nat Commun. 2015; 6:8494. PMC: 4598861. DOI: 10.1038/ncomms9494. View

12.

Li B, Dong C, Wang Y, Li Q . 20(S)-Ginsenoside Rh2 suppresses proliferation and migration of hepatocellular carcinoma cells by targeting EZH2 to regulate CDKN2A-2B gene cluster transcription. Eur J Pharmacol. 2017; 815:173-180. DOI: 10.1016/j.ejphar.2017.09.023. View

13.

Gao S, Zheng Q, Xu B, Pan C, Li K, Zhao Y . EZH2 represses target genes through H3K27-dependent and H3K27-independent mechanisms in hepatocellular carcinoma. Mol Cancer Res. 2014; 12(10):1388-97. DOI: 10.1158/1541-7786.MCR-14-0034. View

14.

Wang X, Wang D, Ding N, Mi L, Yu H, Wu M . The Synergistic Anti-Tumor Activity of EZH2 Inhibitor SHR2554 and HDAC Inhibitor Chidamide through ORC1 Reduction of DNA Replication Process in Diffuse Large B Cell Lymphoma. Cancers (Basel). 2021; 13(17). PMC: 8428225. DOI: 10.3390/cancers13174249. View

15.

Zhu P, Wang Y, Huang G, Ye B, Liu B, Wu J . lnc-β-Catm elicits EZH2-dependent β-catenin stabilization and sustains liver CSC self-renewal. Nat Struct Mol Biol. 2016; 23(7):631-9. DOI: 10.1038/nsmb.3235. View

16.

Zhang Y, Liu G, Lin C, Liao G, Tang B . Silencing the EZH2 gene by RNA interference reverses the drug resistance of human hepatic multidrug-resistant cancer cells to 5-Fu. Life Sci. 2013; 92(17-19):896-902. DOI: 10.1016/j.lfs.2013.03.010. View

17.

Huang S, Wang Z, Zhou J, Huang J, Zhou L, Luo J . EZH2 Inhibitor GSK126 Suppresses Antitumor Immunity by Driving Production of Myeloid-Derived Suppressor Cells. Cancer Res. 2019; 79(8):2009-2020. DOI: 10.1158/0008-5472.CAN-18-2395. View

18.

Zhang L, Li H, Shereda R, Lu Q, Weisenberger D, OConnell C . DNMT and EZH2 inhibitors synergize to activate therapeutic targets in hepatocellular carcinoma. Cancer Lett. 2022; 548:215899. PMC: 9563073. DOI: 10.1016/j.canlet.2022.215899. View

19.

Moritz L, Trievel R . Structure, mechanism, and regulation of polycomb-repressive complex 2. J Biol Chem. 2017; 293(36):13805-13814. PMC: 6130931. DOI: 10.1074/jbc.R117.800367. View

20.

Wang X, Long Y, Paucek R, Gooding A, Lee T, Burdorf R . Regulation of histone methylation by automethylation of PRC2. Genes Dev. 2019; 33(19-20):1416-1427. PMC: 6771386. DOI: 10.1101/gad.328849.119. View